by Van den Kerkhof M, Mabille D, Hendrickx S, Leprohon P, Mowbray CE, Braillard S, Ouellette M, Maes L, Caljon G. Antimicrobial Agents and Chemotherapy 2020; 00152-20. doi: 10.1128/AAC.00152-20
Summary: Current treatments for leishmaniasis are limited by drug toxicity and the risk of treatment failure, which may be related to parasitic drug resistance. A highly promising antileishmanial chemical series, aminopyrazoles, has resulted from the DNDi drug discovery programme. The authors of this paper performed multiple experiments to anticipate their propensity for resistance development, and conclude that the selection performed does not suggest rapid development of resistance against aminopyrazoles in the field.
